Skip to main content
Erschienen in: Cancer Causes & Control 5/2021

09.03.2021 | Original Paper

The influence of multi-morbidities on colorectal cancer screening recommendations and completion

verfasst von: Gloria D. Coronado, Carrie M. Nielson, Erin M. Keast, Amanda F. Petrik, Jerry M. Suls

Erschienen in: Cancer Causes & Control | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Patients’ chronic disease burden can influence the likelihood that providers will recommend cancer screening and that patients will participate in it. Using data from the STOP CRC pragmatic study, we examined associations between chronic disease burden and colorectal cancer screening recommendation and use.

Methods

Participating STOP CRC clinics (n = 26) received either usual care or training to implement a mailed fecal immunochemical test (FIT) outreach program. Selected clinic patients (n = 60,187 patients) were aged 50–74 and overdue for colorectal cancer screening. We used logistic regression to examine the associations between FIT recommendations and completion and patients’ chronic disease burden, calculated using the Charlson Comorbidity Index and the Chronic Illness and Disability Payment System.

Results

For each index, FIT recommendation odds were 8–9% higher among individuals with minimal chronic disease burden and 13–23% lower among individuals with high chronic disease burden (inverted U-shaped association). Among adults who were ordered a FIT, FIT completion odds were 20% lower for individuals with any, versus no, chronic condition and diminished with increasing disease burden (inverse linear association).

Conclusions

Analysis showed an inverted U-shaped association between patients’ chronic disease burden and providers’ recommendation of a FIT and an inverse linear association between patients’ chronic disease burden and FIT completion. ClinicalTrials.gov registration: NCT01742065
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat American Cancer Society (2019) Cancer Statistics Center. American Cancer Society (2019) Cancer Statistics Center.
2.
Zurück zum Zitat Zauber AG, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD (2012) Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366:687–696CrossRef Zauber AG, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD (2012) Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366:687–696CrossRef
3.
Zurück zum Zitat Centers for Disease Control and Prevention (2016) Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia Department of Health and Human Services, Centers for Disease Control and Prevention. Centers for Disease Control and Prevention (2016) Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia Department of Health and Human Services, Centers for Disease Control and Prevention.
4.
Zurück zum Zitat American Association for Retired Persons Chronic Conditions Among Older Americans; . In: Anderson G, ed. Analysis of Medical Expenditure Panel Survey data from 2005 American Association for Retired Persons Chronic Conditions Among Older Americans; . In: Anderson G, ed. Analysis of Medical Expenditure Panel Survey data from 2005
5.
Zurück zum Zitat Zhao G, Ford ES, Ahluwalia IB, Li C, Mokdad AH (2009) Prevalence and trends of receipt of cancer screenings among US women with diagnosed diabetes. J Gen Intern Med 24:270–275CrossRef Zhao G, Ford ES, Ahluwalia IB, Li C, Mokdad AH (2009) Prevalence and trends of receipt of cancer screenings among US women with diagnosed diabetes. J Gen Intern Med 24:270–275CrossRef
6.
Zurück zum Zitat Heflin MT, Pollak KI, Kuchibhatla MN, Branch LG, Oddone EZ (2006) The impact of health status on physicians’ intentions to offer cancer screening to older women. J Gerontol 61:844–850CrossRef Heflin MT, Pollak KI, Kuchibhatla MN, Branch LG, Oddone EZ (2006) The impact of health status on physicians’ intentions to offer cancer screening to older women. J Gerontol 61:844–850CrossRef
7.
Zurück zum Zitat Fontana SA, Baumann LC, Helberg C, Love RR (1997) The delivery of preventive services in primary care practices according to chronic disease status. Am J Public Health 87:1,190–1,196CrossRef Fontana SA, Baumann LC, Helberg C, Love RR (1997) The delivery of preventive services in primary care practices according to chronic disease status. Am J Public Health 87:1,190–1,196CrossRef
9.
Zurück zum Zitat Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF, Hachey M, Cynkin L, Carter GA, Campbell D, Percy-Laurry A, Zou Z, Schrag D, Hankey BF (2012) The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer 118:5,652–5,662CrossRef Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF, Hachey M, Cynkin L, Carter GA, Campbell D, Percy-Laurry A, Zou Z, Schrag D, Hankey BF (2012) The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer 118:5,652–5,662CrossRef
10.
Zurück zum Zitat Guiriguet C, Pera G, Castells A, Toran P, Grau J, Rivero I, Buron A, Macia F, Vela-Vallespin C, Vilarrubi-Estrella M, Marzo-Castillejo M (2017) Impact of comorbid conditions on participation in an organised colorectal cancer screening programme: a cross-sectional study. BMC Cancer 17:524CrossRef Guiriguet C, Pera G, Castells A, Toran P, Grau J, Rivero I, Buron A, Macia F, Vela-Vallespin C, Vilarrubi-Estrella M, Marzo-Castillejo M (2017) Impact of comorbid conditions on participation in an organised colorectal cancer screening programme: a cross-sectional study. BMC Cancer 17:524CrossRef
11.
Zurück zum Zitat Diaz A, Kang J, Moore SP, Baade P, Langbecker D, Condon JR, Valery PC (2017) Association between comorbidity and participation in breast and cervical cancer screening: A systematic review and meta-analysis. Cancer Epidemiol 47:7–19CrossRef Diaz A, Kang J, Moore SP, Baade P, Langbecker D, Condon JR, Valery PC (2017) Association between comorbidity and participation in breast and cervical cancer screening: A systematic review and meta-analysis. Cancer Epidemiol 47:7–19CrossRef
12.
Zurück zum Zitat Kronick R, Gilmer T, Dreyfus T, Lee L (2000) Improving health-based payment for Medicaid beneficiaries: CDPS. Health Care Financ Rev 21:29–64PubMedPubMedCentral Kronick R, Gilmer T, Dreyfus T, Lee L (2000) Improving health-based payment for Medicaid beneficiaries: CDPS. Health Care Financ Rev 21:29–64PubMedPubMedCentral
14.
Zurück zum Zitat HRSA (2016) 2016 National Health Center Data. HRSA (2016) 2016 National Health Center Data.
15.
Zurück zum Zitat Coronado GD, Petrik AF, Vollmer WM, Taplin SH, Keast EM, Fields S, Green BB (2018) Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial. JAMA Intern Med 178:1,174–1,181CrossRef Coronado GD, Petrik AF, Vollmer WM, Taplin SH, Keast EM, Fields S, Green BB (2018) Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial. JAMA Intern Med 178:1,174–1,181CrossRef
16.
Zurück zum Zitat Coronado GD, Vollmer WM, Petrik A, Taplin SH, Burdick TE, Meenan RT, Green BB (2014) Strategies and Opportunities to STOP Colon Cancer in Priority Populations: Design of a cluster-randomized pragmatic trial. Contemp Clin Trials 38:344–349CrossRef Coronado GD, Vollmer WM, Petrik A, Taplin SH, Burdick TE, Meenan RT, Green BB (2014) Strategies and Opportunities to STOP Colon Cancer in Priority Populations: Design of a cluster-randomized pragmatic trial. Contemp Clin Trials 38:344–349CrossRef
18.
Zurück zum Zitat Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1,130–1,139CrossRef Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1,130–1,139CrossRef
19.
Zurück zum Zitat Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619CrossRef Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619CrossRef
20.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRef
21.
Zurück zum Zitat Haas CB, Phipps AI, Hajat A, Chubak J, Wernli KJ (2019) Time to fecal immunochemical test completion for colorectal cancer screening. Am J Manag Care 25:174–180PubMedPubMedCentral Haas CB, Phipps AI, Hajat A, Chubak J, Wernli KJ (2019) Time to fecal immunochemical test completion for colorectal cancer screening. Am J Manag Care 25:174–180PubMedPubMedCentral
22.
Zurück zum Zitat Klabunde CN, Zheng Y, Quinn VP, Beaber EF, Rutter CM, Halm EA, Chubak J, Doubeni CA, Haas JS, Kamineni A, Schapira MM, Vacek PM, Garcia MP, Corley DA, Consortium P (2016) Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. Am J Prev Med 51:e67-75CrossRef Klabunde CN, Zheng Y, Quinn VP, Beaber EF, Rutter CM, Halm EA, Chubak J, Doubeni CA, Haas JS, Kamineni A, Schapira MM, Vacek PM, Garcia MP, Corley DA, Consortium P (2016) Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. Am J Prev Med 51:e67-75CrossRef
23.
Zurück zum Zitat Gross CP, Fried TR, Tinetti ME, Ross JS, Genao I, Hossain S, Wolf E, Lewis CL (2015) Decision-making and cancer screening: a qualitative study of older adults with multiple chronic conditions. J Geriatr Oncol 6:93–100CrossRef Gross CP, Fried TR, Tinetti ME, Ross JS, Genao I, Hossain S, Wolf E, Lewis CL (2015) Decision-making and cancer screening: a qualitative study of older adults with multiple chronic conditions. J Geriatr Oncol 6:93–100CrossRef
24.
Zurück zum Zitat Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC (2018) Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 68:297–316. https://doi.org/10.3322/caac.21446 (Epub 2018 May 30)CrossRefPubMed Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC (2018) Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 68:297–316. https://​doi.​org/​10.​3322/​caac.​21446 (Epub 2018 May 30)CrossRefPubMed
25.
Zurück zum Zitat Cho H, Klabunde CN, Yabroff KR, Wang Z, Meekins A, Lansdorp-Vogelaar I, Mariotto AB (2013) Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med 159:667–676CrossRef Cho H, Klabunde CN, Yabroff KR, Wang Z, Meekins A, Lansdorp-Vogelaar I, Mariotto AB (2013) Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med 159:667–676CrossRef
26.
Zurück zum Zitat Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ (2017) Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology 153:307–323CrossRef Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ (2017) Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology 153:307–323CrossRef
27.
Zurück zum Zitat Braithwaite D, Walter LC, Izano M, Kerlikowske K (2016) Benefits and Harms of Screening Mammography by Comorbidity and Age: A Qualitative Synthesis of Observational Studies and Decision Analyses. J Gen Intern Med 31:561–572CrossRef Braithwaite D, Walter LC, Izano M, Kerlikowske K (2016) Benefits and Harms of Screening Mammography by Comorbidity and Age: A Qualitative Synthesis of Observational Studies and Decision Analyses. J Gen Intern Med 31:561–572CrossRef
28.
Zurück zum Zitat van Hees F, Saini SD, Lansdorp-Vogelaar I, Vijan S, Meester RG, de Koning HJ, Zauber AG, van Ballegooijen M (2015) Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness. Gastroenterology 149:1,425–1,437CrossRef van Hees F, Saini SD, Lansdorp-Vogelaar I, Vijan S, Meester RG, de Koning HJ, Zauber AG, van Ballegooijen M (2015) Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness. Gastroenterology 149:1,425–1,437CrossRef
29.
Zurück zum Zitat Haggstrom DA, Klabunde CN, Smith JL, Yuan G (2013) Variation in primary care physicians’ colorectal cancer screening recommendations by patient age and comorbidity. J Gen Intern Med 28:18–24CrossRef Haggstrom DA, Klabunde CN, Smith JL, Yuan G (2013) Variation in primary care physicians’ colorectal cancer screening recommendations by patient age and comorbidity. J Gen Intern Med 28:18–24CrossRef
30.
Zurück zum Zitat Liu BY, O’Malley J, Mori M, Fagnan LJ, Lieberman D, Morris CD, Buckley DI, Heintzman JD, Carney PA (2014) The association of type and number of chronic diseases with breast, cervical, and colorectal cancer screening. J Am Board Fam Med 27:669–681CrossRef Liu BY, O’Malley J, Mori M, Fagnan LJ, Lieberman D, Morris CD, Buckley DI, Heintzman JD, Carney PA (2014) The association of type and number of chronic diseases with breast, cervical, and colorectal cancer screening. J Am Board Fam Med 27:669–681CrossRef
31.
Zurück zum Zitat O’Neill TJ, Nguemo JD, Tynan AM, Burchell AN (1999) Antoniou T (2017) Risk of Colorectal Cancer and Associated Mortality in HIV: A Systematic Review and Meta-Analysis. J Acquir Immune Defic Syndr 75:439–447CrossRef O’Neill TJ, Nguemo JD, Tynan AM, Burchell AN (1999) Antoniou T (2017) Risk of Colorectal Cancer and Associated Mortality in HIV: A Systematic Review and Meta-Analysis. J Acquir Immune Defic Syndr 75:439–447CrossRef
32.
Zurück zum Zitat Mani D, Aboulafia DM (2013) Screening guidelines for non-AIDS defining cancers in HIV-infected individuals. Curr Opin Oncol 25:518–525CrossRef Mani D, Aboulafia DM (2013) Screening guidelines for non-AIDS defining cancers in HIV-infected individuals. Curr Opin Oncol 25:518–525CrossRef
33.
Zurück zum Zitat Mannheimer S, Friedland G, Matts J, Child C, Chesney M (2002) The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 34:1,115–1,121CrossRef Mannheimer S, Friedland G, Matts J, Child C, Chesney M (2002) The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 34:1,115–1,121CrossRef
34.
Zurück zum Zitat Cobigo V, Ouellette-Kuntz H, Balogh R, Leung F, Lin E, Lunsky Y (2013) Are cervical and breast cancer screening programmes equitable? The case of women with intellectual and developmental disabilities. J Intellect Disabil Res 57:478–488CrossRef Cobigo V, Ouellette-Kuntz H, Balogh R, Leung F, Lin E, Lunsky Y (2013) Are cervical and breast cancer screening programmes equitable? The case of women with intellectual and developmental disabilities. J Intellect Disabil Res 57:478–488CrossRef
35.
Zurück zum Zitat Guilcher SJ, Lofters A, Glazier RH, Jaglal SB, Voth J, Bayoumi AM (2014) Level of disability, multi-morbidity and breast cancer screening: does severity matter? Prev Med 67:193–198CrossRef Guilcher SJ, Lofters A, Glazier RH, Jaglal SB, Voth J, Bayoumi AM (2014) Level of disability, multi-morbidity and breast cancer screening: does severity matter? Prev Med 67:193–198CrossRef
Metadaten
Titel
The influence of multi-morbidities on colorectal cancer screening recommendations and completion
verfasst von
Gloria D. Coronado
Carrie M. Nielson
Erin M. Keast
Amanda F. Petrik
Jerry M. Suls
Publikationsdatum
09.03.2021
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 5/2021
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-021-01408-2

Weitere Artikel der Ausgabe 5/2021

Cancer Causes & Control 5/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.